Eliminating the label exclusion enables clinicians to consider axi-cel for relapsed/refractory primary CNS lymphoma, despite the disease not being explicitly added as an indicated population. Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results